ASH 2018 | Improving the accuracy of Waldenström’s prognosis
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Jithma Prasad Abeykoon, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses a study that investigated the clinical criteria used to estimate Waldenström’s macroglobulinemia (WM) prognosis at the time of diagnosis. Patients received treatment based on current guidelines. Prognoses were generated using the standard International Prognostic Staging System (IPSS) for WM, as well as an alternative system using criteria such MYD88 status. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Abeykoon explains how the alternative criteria used in the study predicted clinical outcomes to a greater degree of accuracy compared to the IPSS model.
Get great new content delivered to your inboxSign up